复宏汉霖HLX04-O临床试验达主要研究终点
4月2日，复宏汉霖（02696）发布公告，近日其重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项针对湿性年龄相关性黄斑变性(wAMD)的3期临床研究中达到了主要研究终点。
这项研究是多中心、随机、双盲的非劣效试验，旨在比较HLX04-O与雷珠单抗的有效性和安全性。研究结果显示，HLX04-O组第48周最佳矫正视力（BCVA）较基线改善的平均字母数变化结果非劣于雷珠单抗组，且两者的安全性特征相似，表现良好。
HLX04-O是基于本公司自主研发的汉贝泰®（贝伐珠单抗注射液）进行优化的眼科制剂，旨在治疗湿性年龄相关性黄斑变性(wAMD)。截至公告日，HLX04-O的3期临床研究正在中国及多个国际市场有序开展，2024年中国境内针对wAMD适应症的药物销售额预计约为41.8亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10